Methods for the treatment of bladder cancer

Patent metadata

Field	Value
Publication number	US-12251394-B2
Application number	US-201917058817-A
Country	US
Kind code	B2
Filing date	May 31, 2019
Priority date	Jun 1, 2018
Publication date	Mar 18, 2025
Grant date	Mar 18, 2025

Abstract

Provided herein are methods for the treatment of bladder cancer.

First claim

We claim:

1. A method of treating bladder cancer, comprising administering to a patient in need of treatment an effective amount of Compound 1 or a pharmaceutically acceptable salt thereof:

2. The method of claim 1 , wherein said pharmaceutically acceptable salt is a diammonium salt.

3. The method of claim 1 , wherein said pharmaceutical composition or pharmaceutically acceptable salt thereof is administered as part of a pharmaceutical composition further comprising a pharmaceutically acceptable excipient.

4. A method of treating bladder cancer comprising:
identifying an individual having bladder cancer treatable by Compound 1, a pharmaceutically acceptable salt of Compound 1, or a pharmaceutical composition comprising Compound 1 or a pharmaceutically acceptable salt of Compound 1; and
administering to said individual an effective amount of the compound, pharmaceutically acceptable salt or pharmaceutical composition by which the bladder cancer has been identified as treatable.

5. The method of claim 4 , wherein said individual is identified as having a bladder cancer treatable by Compound 1, a pharmaceutically acceptable salt of Compound 1, or a pharmaceutical composition comprising Compound 1 or a pharmaceutically acceptable salt of Compound 1, by a presence of a REF STING variant allele in the patient.

6. A method of treating bladder cancer in a patient having a STING allele selected from the group consisting of a REF STING allele, a WT STING allele, an AQ STING allele, and a HAQ STING allele comprising administering to said patient Compound 1, a pharmaceutically acceptable salt of Compound 1, or a pharmaceutical composition comprising Compound 1 or a pharmaceutically acceptable salt of Compound 1.

7. The method of treating bladder cancer of claim 6 , wherein said patient has a WT STING allele.

8. The method of treating bladder cancer of claim 6 , wherein said patient has a AQ STING allele.

9. The method of treating bladder cancer of claim 6 , wherein said patient has a HAQ STING allele.

10. The method of claim 1 , wherein the administration of Compound 1, a pharmaceutically acceptable salt of Compound 1, or a pharmaceutical composition comprising Compound 1 or a pharmaceutically acceptable salt of Compound 1 is conducted intravesicularlly.

11. The method of claim 1 , wherein the bladder cancer is non-muscle invasive bladder cancer.

12. The method of treating bladder cancer of claim 6 , wherein said patient has a REF STING allele.

Assignees

• Eisai R&D Man Co Ltd

Inventors

• Kim Dae-Shik
• Fang Frank
• Endo Atsushi
• Choi Hyeong-Wook
• Hao Ming-Hong
• Bao Xingfeng
• Huang Kuan-Chun

Classifications

• A61P35/04

  specific for metastasis · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K31/7084 Primary

  Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide · CPC title